Loading clinical trials...
Loading clinical trials...
An Observer-Blinded Phase 3 Study to Evaluate the Safety and Immunogenicity of a Single Booster of the NVX-CoV2373 Vaccine in Adults Previously Vaccinated With the BBIBP-CorV Vaccine
Conditions
Interventions
NVX-CoV2373
BBIBP-CorV vaccine
Locations
2
United Arab Emirates
Cleveland Clinic Abu Dhabi
Abu Dhabi, United Arab Emirates
Sheikh Khalifa Medical City (SKMC)
Abu Dhabi, United Arab Emirates
Start Date
March 18, 2022
Primary Completion Date
May 4, 2023
Completion Date
May 4, 2023
Last Updated
August 2, 2023
NCT04391309
NCT04847141
NCT04863547
NCT04768998
NCT04343261
Lead Sponsor
Cogna Technology Solutions LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions